BRCA Hereditary Breast Carcinoma — knowledge graph · CancerIndex

Knowledge graph · Cancer

BRCA Hereditary Breast Carcinoma

subtype

Identifier: CI-CAN-00002033
Entity page: /cancer/brca-hereditary-breast-carcinoma ↗
Edges: 16

Neighbours: 9 drugs7 trials
Drawn: 16 of 16 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
BRCA Hereditary Breast Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived9 of 9
→ investigated in trials for	Olaparibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	BRCA Hereditary Breast Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Veliparibsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants

BRCA Hereditary Breast Carcinoma studied in …STUDIED_INderived7 of 7
→ studied in	NCT04673448Phase 1 · active not recruiting Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 7 trials mapped (3 active)	—	—	BRCA Hereditary Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02595905Phase 2 · completed Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases · condition mapped CURATED_BROADER · 7 trials mapped (3 active)	—	—	BRCA Hereditary Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05485766Phase 2 · recruiting Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	BRCA Hereditary Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06516289Phase 2 · recruiting Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	BRCA Hereditary Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06065059Phase 1/Phase 2 · terminated Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	BRCA Hereditary Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05763472unknown Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	BRCA Hereditary Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01853306Phase 1 · completed A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors · condition mapped ALIAS · 7 trials mapped (3 active)	—	—	BRCA Hereditary Breast Carcinoma	1	Observed	clinicaltrials	graph →